Merck KGaA Breaks Ground on Facility in China
The new China facility will be Merck KGaA's biopharmaceuticals division's second largest worldwide.
Merck KGaA's biopharmaceuticals division held the groundbreaking ceremony for its new pharmaceutical manufacturing facility in Nantong, China, on Aug. 27, 2014. The new facility, which will be the group's second largest pharmaceutical manufacturing facility worldwide, will focus on the bulk production and packaging of Glucophage, Concor, and Euthyrox, the company's brands for the treatment of diabetes, cardiovascular diseases, and thyroid disorders, respectively. These medicines are referenced in China's essential drug list, and Merck KGaA's biopharmaceutical division is the first and only multinational company in China to dedicate a large-scale, green-field investment to the production of drugs on the list, the company said in a press release.
The construction of the site is scheduled for completion in 2016, with commercial production starting in 2017. The site is designed to comply with the highest international standards in terms of quality, environment, health, and safety. The preservation of the environment is a crucial consideration in the facility’s construction. The company notes it plans to maximize resource efficiency and minimize waste generation in the course of the manufacturing process.
Source: Merck KGaA
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
